Addex Therapeutics to Report 2019 Full Year Audited Results on April 8, 2020

Geneva, Switzerland, April 6, 2020 – Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, will discuss its full year 2019 financial results, provide a business update and review its pipeline during a teleconference and webcast for investors, analysts and the media on Wednesday, April 8, 2020 at 16:00 CEST (15:00 BST/10:00 ET).

Title:                    Addex Full Year 2019 Financial Results Conference Call
Date:                   April 8, 2020
Time:                  16:00 CEST (15:00 BST/10:00 ET)

Joining the Conference Call:
1: In the 10 minutes prior to the call start time, call the appropriate participant dial-in number.   

Dial-In Numbers:

• Switzerland                       [phone]
• UK                                     [phone]
• U.S.A                                [phone]
• Other Countries
  

2: Provide the Operator with the Participation Pin Code: 76258295#
           

Link to live event online:
1: In the 10 minutes prior to the call start time, sign in online by following this link Webex Link.
2: Password: Welcome

About Addex Therapeutics
Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as allosteric modulators for neurological disorders. Allosteric modulators offer several potential advantages over conventional non-allosteric molecules and may offer an improved therapeutic approach to conventional "orthosteric" small molecule or biological drugs. Addex's allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention. Addex's lead drug candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM), is scheduled to enter a pivotal registration clinical trial for Parkinson’s disease levodopa induced dyskinesia (PD-LID). In parallel, dipraglurant's therapeutic use in dystonia is being investigated in preclinical models. Addex's second clinical program, ADX71149 (mGlu2 positive allosteric modulator or PAM) is being developed in collaboration with Janssen Pharmaceuticals, Inc for the treatment of epilepsy. In addition, Addex’s GABA_B PAM program has been licensed to Indivior PLC for the treatment of addiction. Preclinical programs include GABA_B PAM for CMT1A, mGlu7 NAM for PTSD, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinson’s disease and mGlu3 PAM for neurodegenerative disorders.